GlassScriptPhysician profile
Dhaval G Aghera
NPI 1679885149
$4,090.45
in general payments reported to CMS, 2019-2025
27 companies · $520 in 2025
The $520 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $504 · 2020: $419 · 2021: $559 · 2022: $796 · 2023: $667 · 2024: $626 · 2025: $520.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,735 · Education: $78.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,734.54 |
| Education | $78.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $570.73 | 2020-2025 | Farxiga |
| Mallinckrodt Hospital Products INC. | $454.87 | 2020-2024 | Acthar |
| Horizon Therapeutics Plc | $428.75 | 2021-2023 | Krystexxa |
| Amgen INC. | $336.51 | 2021-2025 | Tavneos, Krystexxa, Aranesp |
| Bayer Healthcare Pharmaceuticals INC. | $274.21 | 2021-2025 | |
| Akebia Therapeutics INC | $246.26 | 2020-2025 | Vafseo |
| Vifor Pharma, INC. | $221.34 | 2020-2025 | Veltassa |
| Aurinia Pharma U.S., INC. | $212.42 | 2023-2025 | Lupkynis |
| Mallinckrodt Enterprises LLC | $147.14 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $119.76 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $113.32 | 2019-2025 | |
| Glaxosmithkline, LLC. | $108.14 | 2023-2025 | Benlysta, Jesduvroq |
| Ani Pharmaceuticals, INC. | $103.81 | 2022 | |
| Janssen Pharmaceuticals, INC | $100.72 | 2019-2020 | |
| Travere Therapeutics, INC. | $99.92 | 2023-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $86.52 | 2020-2025 | Velphoro |
| Pfizer INC. | $79.26 | 2019 | |
| Calliditas Therapeutics US INC. | $77.24 | 2022-2025 | Tarpeyo |
| Alnylam Pharmaceuticals INC. | $71.39 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.86 | 2025 | Jardiance |
| Allergan, INC. | $41.66 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $40.62 | 2022 | |
| Scpharmaceuticals INC. | $35.75 | 2025 | |
| Medtronic, INC. | $22.13 | 2023 | Ellipsys Vascular Access System |
| Ardelyx, INC. | $19.49 | 2025 | Ibsrela |
| Genentech USA, INC. | $17.92 | 2025 | Gazyva |
| Alexion Pharmaceuticals, INC. | $15.71 | 2025 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dhaval Aghera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.